Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study
1997

Comparing Toremifene and Tamoxifen for Breast Cancer Treatment

Sample size: 415 publication Evidence: moderate

Author Information

Author(s): S Pyrhonen, R Valavaara, H Modig, M Pawlicki, T Pienkowski, S Gundersen, J Bauer, G Westman, S Lundgren, G Blanco, O Melia, I Nilsson, T Hietanen, I Hindy, J Vuorinen, A Hajba

Hypothesis

Is toremifene as effective and safe as tamoxifen in treating post-menopausal patients with advanced breast cancer?

Conclusion

Toremifene and tamoxifen are equally effective and safe for treating advanced breast cancer in post-menopausal women.

Supporting Evidence

  • The response rate for toremifene was 31.3% and for tamoxifen was 37.3%.
  • The median time to progression was 7.3 months for toremifene and 10.2 months for tamoxifen.
  • Toremifene had a lower discontinuation rate due to adverse events compared to tamoxifen.
  • Both treatments were well tolerated with mild to moderate adverse effects.

Takeaway

This study looked at two medicines for breast cancer and found that they work just as well as each other.

Methodology

A double-blind, randomized trial comparing toremifene and tamoxifen in 415 post-menopausal patients with advanced breast cancer.

Potential Biases

Potential imbalance in estrogen receptor levels between treatment groups.

Limitations

The study had a high proportion of patients with unknown estrogen receptor status, which may have affected the results.

Participant Demographics

Post-menopausal women with advanced breast cancer, aged 33.6 to 87.6 years.

Statistical Information

P-Value

0.215

Confidence Interval

-15.1% to 3.1%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication